Fig. 1From: Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapyWaterfall plot of PSA response. PSA responses of ≥0 %, ≥30 %, and ≥50 % are seen in 69 (87.3 %), 64 (81.0 %), and 55 (69.6 %) patients, respectivelyBack to article page